Matches in SemOpenAlex for { <https://semopenalex.org/work/W2805663123> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2805663123 endingPage "e10" @default.
- W2805663123 startingPage "e10" @default.
- W2805663123 abstract "Objective: Diabetes is a condition of high cardiovascular risk and drug treatment for secondary prevention of cardiovascular disease is an establish strategy recommended by guidelines. However, a wide gap exists between what the guidelines say and the real life in terms of number of class of drugs. The objective of the SATURNO study was to assess in diabetic subjects what is the impact on mortality of the gap in subjects after stroke or transitory ischemic attack (TIA), myocardial infarction (MI) or coronary revascularization (REV) based on data from Electronic Health Records (EHR). <FILE IMAGE=’526_20171222055618.jpg’>Design and method: Subjects and methods: Patients with diabetes and a diagnosis of stroke, TIA. MI or REV after January 1st , 2011 were selected from the EHR of the Valencia Community which contain all drug prescriptions. In the present study, three groups of therapy usually recommended for secondary prevention or for control of main cardiovascular risk factors were selected: aspirin, SRA blockers (ACEi or ARB) and statins. All cause mortality was obtained from official register during an observational period of 1.7+1.5 years. The survival analysis models were adjusted for group (group 0, group1, group 2, group 3), age (continuous), gender (male, female), systolic blood pressure (continuous), LDL-cholesterol (continuous), HDL-cholesterol (continuous) and diabetes treatment (yes, no). We further adjusted for hypertension treatment (yes, no) and hypertension (yes, no) (Model 2) and for dyslipidemia treatment (yes, no) and dyslipidemia (yes, no) (Model 3). R Results: : A total of 38752 patients (61% men, mean age 73 yr) were included, 22502 with stroke or TIA, MI 11692 and REV 4363. The number of subjects in each group, the number of subjects and the HRs are in the table and the survival curves in the figure Conclusions: In conclusion, the gap between guidelines and reality in the use of cardiovascular protecting drugs largely influence all cause mortality in diabetic subjects." @default.
- W2805663123 created "2018-06-13" @default.
- W2805663123 creator A5007735183 @default.
- W2805663123 creator A5011456130 @default.
- W2805663123 creator A5018993565 @default.
- W2805663123 creator A5019471619 @default.
- W2805663123 creator A5025254249 @default.
- W2805663123 creator A5035532716 @default.
- W2805663123 creator A5076744575 @default.
- W2805663123 creator A5083496716 @default.
- W2805663123 creator A5088712446 @default.
- W2805663123 date "2018-06-01" @default.
- W2805663123 modified "2023-09-25" @default.
- W2805663123 title "IMPACT ON MORTALITY OF THE GAP IN THE USE OF CARDIOVASCULAR PREVENTING DRUGS IN DIABETES" @default.
- W2805663123 doi "https://doi.org/10.1097/01.hjh.0000538988.02599.7e" @default.
- W2805663123 hasPublicationYear "2018" @default.
- W2805663123 type Work @default.
- W2805663123 sameAs 2805663123 @default.
- W2805663123 citedByCount "0" @default.
- W2805663123 crossrefType "journal-article" @default.
- W2805663123 hasAuthorship W2805663123A5007735183 @default.
- W2805663123 hasAuthorship W2805663123A5011456130 @default.
- W2805663123 hasAuthorship W2805663123A5018993565 @default.
- W2805663123 hasAuthorship W2805663123A5019471619 @default.
- W2805663123 hasAuthorship W2805663123A5025254249 @default.
- W2805663123 hasAuthorship W2805663123A5035532716 @default.
- W2805663123 hasAuthorship W2805663123A5076744575 @default.
- W2805663123 hasAuthorship W2805663123A5083496716 @default.
- W2805663123 hasAuthorship W2805663123A5088712446 @default.
- W2805663123 hasConcept C126322002 @default.
- W2805663123 hasConcept C127413603 @default.
- W2805663123 hasConcept C134018914 @default.
- W2805663123 hasConcept C164705383 @default.
- W2805663123 hasConcept C23131810 @default.
- W2805663123 hasConcept C2777628954 @default.
- W2805663123 hasConcept C2778096610 @default.
- W2805663123 hasConcept C2779134260 @default.
- W2805663123 hasConcept C2779464278 @default.
- W2805663123 hasConcept C2780645631 @default.
- W2805663123 hasConcept C500558357 @default.
- W2805663123 hasConcept C555293320 @default.
- W2805663123 hasConcept C71924100 @default.
- W2805663123 hasConcept C78519656 @default.
- W2805663123 hasConcept C84393581 @default.
- W2805663123 hasConceptScore W2805663123C126322002 @default.
- W2805663123 hasConceptScore W2805663123C127413603 @default.
- W2805663123 hasConceptScore W2805663123C134018914 @default.
- W2805663123 hasConceptScore W2805663123C164705383 @default.
- W2805663123 hasConceptScore W2805663123C23131810 @default.
- W2805663123 hasConceptScore W2805663123C2777628954 @default.
- W2805663123 hasConceptScore W2805663123C2778096610 @default.
- W2805663123 hasConceptScore W2805663123C2779134260 @default.
- W2805663123 hasConceptScore W2805663123C2779464278 @default.
- W2805663123 hasConceptScore W2805663123C2780645631 @default.
- W2805663123 hasConceptScore W2805663123C500558357 @default.
- W2805663123 hasConceptScore W2805663123C555293320 @default.
- W2805663123 hasConceptScore W2805663123C71924100 @default.
- W2805663123 hasConceptScore W2805663123C78519656 @default.
- W2805663123 hasConceptScore W2805663123C84393581 @default.
- W2805663123 hasIssue "Supplement 1" @default.
- W2805663123 hasLocation W28056631231 @default.
- W2805663123 hasOpenAccess W2805663123 @default.
- W2805663123 hasPrimaryLocation W28056631231 @default.
- W2805663123 hasRelatedWork W2022742281 @default.
- W2805663123 hasRelatedWork W2049397185 @default.
- W2805663123 hasRelatedWork W2399063111 @default.
- W2805663123 hasRelatedWork W2752212858 @default.
- W2805663123 hasRelatedWork W2794495824 @default.
- W2805663123 hasRelatedWork W3112891903 @default.
- W2805663123 hasRelatedWork W3158431806 @default.
- W2805663123 hasRelatedWork W3208382594 @default.
- W2805663123 hasRelatedWork W4229452857 @default.
- W2805663123 hasRelatedWork W1897993212 @default.
- W2805663123 hasVolume "36" @default.
- W2805663123 isParatext "false" @default.
- W2805663123 isRetracted "false" @default.
- W2805663123 magId "2805663123" @default.
- W2805663123 workType "article" @default.
%2C%20myocardial%20infarction%20(MI)%20or%20coronary%20revascularization%20(REV)%20based%20on%20data%20from%20Electronic%20Health%20Records%20(EHR).%20%3CFILE%20IMAGE%3D%E2%80%99526_20171222055618.jpg%E2%80%99%3EDesign%20and%20method%3A%20Subjects%20and%20methods%3A%20Patients%20with%20diabetes%20and%20a%20diagnosis%20of%20stroke%2C%20TIA.%20MI%20or%20REV%20after%20January%201st%20%2C%202011%20were%20selected%20from%20the%20EHR%20of%20the%20Valencia%20Community%20which%20contain%20all%20drug%20prescriptions.%20In%20the%20present%20study%2C%20three%20groups%20of%20therapy%20usually%20recommended%20for%20secondary%20prevention%20or%20for%20control%20of%20main%20cardiovascular%20risk%20factors%20were%20selected%3A%20aspirin%2C%20SRA%20blockers%20(ACEi%20or%20ARB)%20and%20statins.%20All%20cause%20mortality%20was%20obtained%20from%20official%20register%20during%20an%20observational%20period%20of%201.7%2B1.5%20years.%20The%20survival%20analysis%20models%20were%20adjusted%20for%20group%20(group%200%2C%20group1%2C%20group%202%2C%20group%203)%2C%20age%20(continuous)%2C%20gender%20(male%2C%20female)%2C%20systolic%20blood%20pressure%20(continuous)%2C%20LDL-cholesterol%20(continuous)%2C%20HDL-cholesterol%20(continuous)%20and%20diabetes%20treatment%20(yes%2C%20no).%20We%20further%20adjusted%20for%20hypertension%20treatment%20(yes%2C%20no)%20and%20hypertension%20(yes%2C%20no)%20(Model%202)%20and%20for%20dyslipidemia%20treatment%20(yes%2C%20no)%20and%20dyslipidemia%20(yes%2C%20no)%20(Model%203).%20R%20Results%3A%20%3A%20A%20total%20of%2038752%20patients%20(61%25%20men%2C%20mean%20age%2073%20yr)%20were%20included%2C%2022502%20with%20stroke%20or%20TIA%2C%20MI%2011692%20and%20REV%204363.%20The%20number%20of%20subjects%20in%20each%20group%2C%20the%20number%20of%20subjects%20and%20the%20HRs%20are%20in%20the%20table%20and%20the%20survival%20curves%20in%20the%20figure%20Conclusions%3A%20In%20conclusion%2C%20the%20gap%20between%20guidelines%20and%20reality%20in%20the%20use%20of%20cardiovascular%20protecting%20drugs%20largely%20influence%20all%20cause%20mortality%20in%20diabetic%20subjects.%22){kind=link}